BIOCRYST PHARMACEUTICALS INC Insider Trading for March 2017
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in BIOCRYST PHARMACEUTICALS INC.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in BIOCRYST PHARMACEUTICALS INC for March 2017.
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Mar 22 2017 | BCRX | BIOCRYST PHARMACEU ... | STAAB THOMAS R II | Senior Vice Preside ... | Option Exercise | M | 3.78 | 3,250 | 12,285 | 55,805 | |
Mar 22 2017 | BCRX | BIOCRYST PHARMACEU ... | STAAB THOMAS R II | Senior Vice Preside ... | Sell | S | 9.20 | 3,250 | 29,900 | 141,460 | 144.7 K to 141.5 K (-2.25 %) |
Mar 22 2017 | BCRX | BIOCRYST PHARMACEU ... | STAAB THOMAS R II | Senior Vice Preside ... | Buy | M | 3.78 | 3,250 | 12,285 | 144,710 | 141.5 K to 144.7 K (+2.30 %) |
Mar 20 2017 | BCRX | BIOCRYST PHARMACEU ... | STAAB THOMAS R II | Senior Vice Preside ... | Option Exercise | M | 1.42 | 12,500 | 17,750 | 75,000 | |
Mar 20 2017 | BCRX | BIOCRYST PHARMACEU ... | STAAB THOMAS R II | Senior Vice Preside ... | Option Exercise | M | 3.78 | 23,955 | 90,550 | 59,055 | |
Mar 20 2017 | BCRX | BIOCRYST PHARMACEU ... | STAAB THOMAS R II | Senior Vice Preside ... | Payment of Exercise | F | 8.80 | 12,308 | 108,310 | 141,460 | 153.8 K to 141.5 K (-8.00 %) |
Mar 20 2017 | BCRX | BIOCRYST PHARMACEU ... | STAAB THOMAS R II | Senior Vice Preside ... | Buy | M | 1.42 | 12,500 | 17,750 | 153,768 | 141.3 K to 153.8 K (+8.85 %) |
Mar 20 2017 | BCRX | BIOCRYST PHARMACEU ... | STAAB THOMAS R II | Senior Vice Preside ... | Buy | M | 3.78 | 23,955 | 90,550 | 141,268 | 117.3 K to 141.3 K (+20.42 %) |
Mar 14 2017 | BCRX | BIOCRYST PHARMACEU ... | STAAB THOMAS R II | Senior Vice Preside ... | Option Exercise | M | 3.78 | 3,250 | 12,285 | 83,010 | |
Mar 14 2017 | BCRX | BIOCRYST PHARMACEU ... | STAAB THOMAS R II | Senior Vice Preside ... | Sell | S | 9.06 | 3,250 | 29,445 | 117,313 | 120.6 K to 117.3 K (-2.70 %) |
Mar 14 2017 | BCRX | BIOCRYST PHARMACEU ... | STAAB THOMAS R II | Senior Vice Preside ... | Buy | M | 3.78 | 3,250 | 12,285 | 120,563 | 117.3 K to 120.6 K (+2.77 %) |
Mar 10 2017 | BCRX | BIOCRYST PHARMACEU ... | STAAB THOMAS R II | Senior Vice Preside ... | Option Exercise | M | 3.78 | 6,500 | 24,570 | 86,260 | |
Mar 10 2017 | BCRX | BIOCRYST PHARMACEU ... | STAAB THOMAS R II | Senior Vice Preside ... | Sell | S | 8.65 | 3,250 | 28,113 | 117,313 | 120.6 K to 117.3 K (-2.70 %) |
Mar 10 2017 | BCRX | BIOCRYST PHARMACEU ... | STAAB THOMAS R II | Senior Vice Preside ... | Sell | S | 8.20 | 3,250 | 26,650 | 120,563 | 123.8 K to 120.6 K (-2.62 %) |
Mar 10 2017 | BCRX | BIOCRYST PHARMACEU ... | STAAB THOMAS R II | Senior Vice Preside ... | Buy | M | 3.78 | 6,500 | 24,570 | 123,813 | 117.3 K to 123.8 K (+5.54 %) |
Mar 08 2017 | BCRX | BIOCRYST PHARMACEU ... | STAAB THOMAS R II | Senior Vice Preside ... | Option Exercise | M | 3.78 | 3,250 | 12,285 | 92,760 | |
Mar 08 2017 | BCRX | BIOCRYST PHARMACEU ... | STAAB THOMAS R II | Senior Vice Preside ... | Sell | S | 7.90 | 3,250 | 25,675 | 117,313 | 120.6 K to 117.3 K (-2.70 %) |
Mar 08 2017 | BCRX | BIOCRYST PHARMACEU ... | STAAB THOMAS R II | Senior Vice Preside ... | Buy | M | 3.78 | 3,250 | 12,285 | 120,563 | 117.3 K to 120.6 K (+2.77 %) |
Mar 02 2017 | BCRX | BIOCRYST PHARMACEU ... | INGRAM ROBERT ALEXANDER | Director | Grant | A | 6.24 | 1,602 | 9,996 | 5,823 | 4.2 K to 5.8 K (+37.95 %) |
Mar 02 2017 | BCRX | BIOCRYST PHARMACEU ... | Hutson Nancy J | Director | Grant | A | 6.24 | 1,602 | 9,996 | 30,266 | 28.7 K to 30.3 K (+5.59 %) |
Mar 02 2017 | BCRX | BIOCRYST PHARMACEU ... | Cohen Fred E | Director | Grant | A | 6.24 | 1,602 | 9,996 | 117,469 | 115.9 K to 117.5 K (+1.38 %) |
Mar 01 2017 | BCRX | BIOCRYST PHARMACEU ... | Powell Lynne | Senior VP - CCO | Option Exercise | A | 5.51 | 150,000 | 826,500 | 150,000 | |
Mar 01 2017 | BCRX | BIOCRYST PHARMACEU ... | Barnes Alane P | VP, General Counsel ... | Option Exercise | A | 5.51 | 150,000 | 826,500 | 150,000 | |
Mar 01 2017 | BCRX | BIOCRYST PHARMACEU ... | Babu Yarlagadda S | Senior VP - Drug Di ... | Option Exercise | A | 5.51 | 175,000 | 964,250 | 175,000 | |
Mar 01 2017 | BCRX | BIOCRYST PHARMACEU ... | Sheridan William P | Senior VP - CMO | Option Exercise | A | 5.51 | 175,000 | 964,250 | 175,000 | |
Mar 01 2017 | BCRX | BIOCRYST PHARMACEU ... | STAAB THOMAS R II | Senior Vice Preside ... | Option Exercise | A | 5.51 | 175,000 | 964,250 | 175,000 | |
Mar 01 2017 | BCRX | BIOCRYST PHARMACEU ... | Stonehouse Jon P | President & CEO | Option Exercise | A | 5.51 | 500,000 | 2,755,000 | 500,000 |